Myriad inks coverage deal for prostate cancer test

Myriad Genetics ($MYGN) is focused on expanding reimbursement for its genetic tests, recently gaining Medicare coverage for its prostate cancer screening tool, Prolaris. As part of its latest coverage push, the company inked a three-year contract with Tufts Health Plan to provide its Prolaris biopsy test for members diagnosed with localized prostate cancer. The test could help guide treatment decisions for men with the disease, especially as recent data show that many individuals do not benefit from interventional treatment or suffer side effects from radical prostatectomy and radiation. "Myriad is excited to offer Prolaris testing to Tufts Health Plan's members. We believe it will help to improve patient care and lower healthcare costs," Nicole Lambert, general manager of Myriad's Urology Business Unit, said in a statement. Statement